Achillion Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Achillion Pharmaceuticals, Inc.
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.
Drug Discovery Tools
- Drug Discovery Tools